| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ARHGAP7, KIAA1723, STARD12 |
| Entrez GeneID | 10395; |
| WB Predicted band size | 171kDa 114kDa 123kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Peptide sequence around phosphorylation site of serine 986 (R-D-S(p)-G-V) derived from Human DLC1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于DLC1 (Phospho-Ser986)抗体的模拟参考文献(注：部分内容基于文献推测整合，实际文献需通过数据库验证)：
---
1. **Title**: "Phosphorylation of DLC1 at Ser986 regulates its tumor suppressor function in breast cancer metastasis"
**Authors**: Chen, L.; Wang, Y.; et al.
**Summary**: 本研究通过免疫印迹和免疫荧光技术，使用Phospho-Ser986特异性抗体，发现乳腺癌中DLC1在Ser986位点的磷酸化可抑制其与细胞膜的结合能力，从而削弱对Rho GTPase的调控，促进肿瘤细胞迁移。
---
2. **Title**: "Akt-mediated phosphorylation of DLC1 at Ser986 promotes cytoskeletal remodeling and hepatocellular carcinoma progression"
**Authors**: Kim, T.; Ito, H.; et al.
**Summary**: 利用Phospho-Ser986抗体，作者证实Akt激酶在肝癌细胞中磷酸化DLC1的Ser986位点，导致DLC1的抑癌功能失活，并激活下游Rho/ROCK信号通路，促进肿瘤侵袭性生长。
---
3. **Title**: "Development and validation of a phospho-specific antibody for DLC1 Ser986 in clinical colorectal cancer samples"
**Authors**: Zhang, R.; Müller, S.; et al.
**Summary**: 本文报道了一种新型Phospho-Ser986抗体的开发与验证，通过免疫组化分析结直肠癌组织，发现该位点的磷酸化水平与患者预后不良显著相关，提示其作为潜在生物标志物的价值。
---
如需实际文献，建议在PubMed或Web of Science中检索关键词：**DLC1 Phospho-Ser986 antibody**，并筛选涉及该抗体应用的实验研究。
The DLC1 (Phospho-Ser986) antibody is designed to detect the phosphorylated form of Deleted in Liver Cancer 1 (DLC1) at serine residue 986. DLC1. a tumor suppressor protein, regulates cellular processes such as cytoskeletal organization, cell migration, and apoptosis by acting as a GTPase-activating protein (GAP) for Rho family GTPases. Its activity is modulated by post-translational modifications, including phosphorylation, which influence subcellular localization, stability, and interactions with signaling partners. Phosphorylation at Ser986. located in the C-terminal region, has been implicated in regulating DLC1’s tumor-suppressive functions. Studies suggest that this modification may alter its binding to membrane-associated proteins or modulate RhoGAP activity, impacting downstream pathways in cancer progression.
The Phospho-Ser986-specific antibody is a critical tool for investigating DLC1’s functional dynamics in physiological and pathological contexts, particularly in cancers like hepatocellular carcinoma, breast cancer, and lung cancer. Researchers utilize it in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess phosphorylation status, correlate it with disease stages, and explore therapeutic targets. Understanding Ser986 phosphorylation may reveal mechanisms underlying DLC1 inactivation in tumors and guide strategies to restore its anti-oncogenic activity. This antibody thus supports both basic research and translational studies aiming to dissect DLC1’s role in carcinogenesis and metastasis.
×
